iPS-derived MSCs from an expandable bank to deliver a prodrug-converting enzyme that limits growth and metastases of human breast cancers

Mostrar otras versiones (1)

One attractive strategy to treat cancers is to deliver an exogenous enzyme that will convert a non-toxic compound to a highly toxic derivative. The strategy was tested with viral vectors but was disappointing because the efficiency of transduction into tumor cells was too low. Recent reports demonst...

Descripción completa

Detalles Bibliográficos
Autores principales: Ullah, M, Kuroda, Y, Bartosh, T J, Liu, F, Zhao, Q, Gregory, C, Reger, R, Xu, J, Lee, R H, Prockop, D J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292869/
https://www.ncbi.nlm.nih.gov/pubmed/28179988
http://dx.doi.org/10.1038/cddiscovery.2016.64

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292869/
https://www.ncbi.nlm.nih.gov/pubmed/28179988
http://dx.doi.org/10.1038/cddiscovery.2016.64

Ejemplares similares